Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury

Cardiovascular Research

Volumn 113, Issue 14, 2017, Pages 1753-1762

  Barhoumi, Tlili ^a   Fraulob Aquino, Julio C ^a   Mian, Muhammad Oneeb Rehman ^a   Ouerd, Sofiane ^a   Idris Khodja, Noureddine ^a   Huo, Ku Geng ^a   Rehman, Asia ^a   Caillon, Antoine ^a   Dancose Giambattisto, Bianca ^a   Ebrahimian, Talin ^a   Lehoux, Stéphanie ^a   Paradis, Pierre ^a   Schiffrin, Ernesto L ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Blood pressure; Bone marrow transplantation; Hypertension; MMP2; Vascular injury

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; CD69 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; RECOMBINANT GELATINASE A; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTIC MEDIA; ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL INJURY; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FRACTIONATION; CELL ISOLATION; CONTROLLED STUDY; DRUG INFUSION; ENDOTHELIAL DYSFUNCTION; HYPERTENSION; HYPERTROPHY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MESENTERIC ARTERY; MONOCYTE; MOUSE; NONHUMAN; PERIVASCULAR ADIPOSE TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE; VASCULAR SMOOTH MUSCLE CELL; VASODILATATION; WILD TYPE; ANIMAL; BLOOD PRESSURE; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECT; GENETICS; KNOCKOUT MOUSE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SMOOTH MUSCLE CELL; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 2; MESENTERIC ARTERIES; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; OXIDATIVE STRESS; VASCULAR SYSTEM INJURIES;

EID: 85040120579     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvx115     Document Type: Article

References (41)

1. Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension 2012;59:367-374.
2. Paradis P, Schiffrin EL, Renin-angiotensin-aldosterone system and pathobiology of hypertension. In WC DeMello, ED Frohlich (eds). Renin Angiotensin System and Cardiovascular Disease. New York, N.Y.: Humana Press, 2009. pp. 35-58.
3. Idris-Khodja N, Mian MO, Paradis P, Schiffrin EL. Dual opposing roles of adaptive immunity in hypertension. Eur Heart J 2014;35:1238-1244.
4. Mian MO, Paradis P, Schiffrin EL. Innate immunity in hypertension. Curr Hypertens Rep 2014;16:413.
5. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta 2012;413:656-662.
6. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008;29:367-374.
7. Wang M, Kim SH, Monticone RE, Lakatta EG. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension 2015; 65:698-703.
8. Berry E, Bosonea AM, Wang X, Fernandez-Patron C. Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease. J Vasc Res 2013;50:52-68.
9. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617-629.
10. Zavadzkas JA, Stroud RE, Bouges S, Mukherjee R, Jones JR, Patel RK, McDermott PJ, Spinale FG. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res 2014;114:1435-1445.
11. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001;276:7957-7962.
12. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003;116:217-224.
13. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999;85:906-911.
14. Marchesi C, Dentali F, Nicolini E, Maresca AM, Tayebjee MH, Franz M, Guasti L, Venco A, Schiffrin EL, Lip GY, Grandi AM. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens 2012;30:3-16.
15. Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, Kassiri Z, Fernandez-Patron C. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011;57:123-130.
16. Wu J, Thabet SR, Kirabo A, Trott DW, Saleh MA, Xiao L, Madhur MS, Chen W, Harrison DG. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circ Res 2014;114:616-625.
17. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008;198:320-331.
18. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 2005;45:432-437.
19. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, Kinugawa S, Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006;47:711-717.
20. Wang X, Berry E, Hernandez-Anzaldo S, Takawale A, Kassiri Z, Fernandez-Patron C. Matrix metalloproteinase-2 mediates a mechanism of metabolic cardioprotection consisting of negative regulation of the sterol regulatory element-binding protein-2/ 3-hydroxy-3-methylglutaryl-CoA reductase pathway in the heart. Hypertension 2015;65:882-888.
21. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2006;26:1120-1125.
22. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 2011;57:469-476.
23. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002;105:2296-2302.
24. Li MW, Mian MO, Barhoumi T, Rehman A, Mann K, Paradis P, Schiffrin EL. Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2013;33:2306-2315.
25. Ebrahimian T, Simon D, Lemarie CA, Simeone S, Heidari M, Mann KK, Wassmann S, Lehoux S. Absence of four-and-a-half LIM domain protein 2 decreases atherosclerosis in ApoE-/-mice. Arterioscler Thromb Vasc Biol 2015;35:1190-1197.
26. Briet M, Barhoumi T, Mian MO, Coelho SC, Ouerd S, Rautureau Y, Coffman TM, Paradis P, Schiffrin EL. Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin type 1a receptors. Hypertension 2016;67:897-905.
27. Shah BH, Catt KJ. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy. Trends Endocrinol Metab 2004;15:241-243.
28. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008; 28:2108-2114.
29. Oviedo-Orta E, Bermudez-Fajardo A, Karanam S, Benbow U, Newby AC. Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology 2008;124:42-50.
30. Chowdhury A, Sarkar J, Pramanik PK, Chakraborti T, Chakraborti S. Cross talk between MMP2-Spm-Cer-S1P and ERK1/2 in proliferation of pulmonary artery smooth muscle cells under angiotensin II stimulation. Arch Biochem Biophys 2016; 603:91-101.
31. Luchtefeld M, Grote K, Grothusen C, Bley S, Bandlow N, Selle T, Struber M, Haverich A, Bavendiek U, Drexler H, Schieffer B. Angiotensin II induces MMP-2 in a p47phox-dependent manner. Biochem Biophys Res Commun 2005;328:183-188.
32. Wang C, Chang Q, Sun X, Qian X, Liu P, Pei H, Guo X, Liu W. Angiotensin II induces an increase in matrix metalloproteinase 2 expression in aortic smooth muscle cells of ascending thoracic aortic aneurysms through JNK, ERK1/2, and p38 MAPK activation. J Cardiovasc Pharmacol 2015;66:285-293.
33. Wang C, Qian X, Sun X, Chang Q. Angiotensin II increases matrix metalloproteinase 2 expression in human aortic smooth muscle cells via AT1R and ERK1/2. Exp Biol Med (Maywood) 2015;240:1564-1571.
34. Shen M, Lee J, Basu R, Sakamuri SS, Wang X, Fan D, Kassiri Z. Divergent roles of matrix metalloproteinase 2 in pathogenesis of thoracic aortic aneurysm. Arterioscler Thromb Vasc Biol 2015;35:888-898.
35. Schreier B, Hunerberg M, Rabe S, Mildenberger S, Bethmann D, Heise C, Sibilia M, Offermanns S, Gekle M. Consequences of postnatal vascular smooth muscle EGFR deletion on acute angiotensin II action. Clin Sci (Lond) 2016;130:19-33.
36. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999;104:1693-1701.
37. Chan G, Nogalski MT, Yurochko AD. Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. Proc Natl Acad Sci U S A 2009;106:22369-22374.
38. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA. The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis 2006;186:38-53.
39. Mian MO, Barhoumi T, Briet M, Paradis P, Schiffrin EL. Deficiency of T-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J Hypertens 2016;34:97-108.
40. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 2005;25:2106-2113.
41. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent aldosteroneinduced vascular injury. Hypertension 2012;59:324-330.